CRISPR Therapeutics
@CRISPRTX
Followers
22,129
Following
0
Media
244
Statuses
407
Explore trending content on Musk Viewer
Brighton
• 213321 Tweets
#FNTHWIN
• 164571 Tweets
花火大会
• 155780 Tweets
#Forever8estie7DREAM
• 150449 Tweets
Manchester United
• 138048 Tweets
7DREAM 8TH ANNIVERSARY
• 127123 Tweets
FAYE YOKO RECAP BLANK SS2EP3
• 114721 Tweets
#드림8ᅧ원하세요_시즈니도8ᅧ원할게요
• 79106 Tweets
FULL TIME
• 70513 Tweets
Ipswich
• 70364 Tweets
Amad
• 62606 Tweets
Haaland
• 57002 Tweets
Foo Fighters
• 56282 Tweets
Rashford
• 53148 Tweets
Lewis
• 51293 Tweets
Zirkzee
• 51141 Tweets
#SixTONESANN
• 49234 Tweets
Mount
• 47488 Tweets
Garnacho
• 41697 Tweets
最高のチーム
• 39592 Tweets
Everton
• 38385 Tweets
Maguire
• 35365 Tweets
Man U
• 30344 Tweets
韓国オンニ
• 27398 Tweets
Hamilton
• 26960 Tweets
#나의_여름_도운아_생일축하해
• 26212 Tweets
嫌いボタン
• 25786 Tweets
Norris
• 25592 Tweets
Lando
• 23207 Tweets
Welbeck
• 22308 Tweets
Joao Pedro
• 21999 Tweets
ブライトン
• 18379 Tweets
Savinho
• 14226 Tweets
クマムシ
• 12829 Tweets
Dani Olmo
• 12073 Tweets
Sainz
• 12007 Tweets
#Breaking
: The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for
#SickleCellDisease
. Learn more:
22
138
488
The UK Medicines and Healthcare products Regulatory Agency approves the CRISPR/Cas9 gene-edited treatment for
#SickleCellDisease
&
#BetaThalassemia
in Great Britain. This is a historic milestone arising out of our collaboration with Vertex. Learn more:
21
120
460
The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for transfusion-dependent beta thalassemia. Learn more:
9
69
301
#Breaking
: The European Commission approves CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for
#SickleCellDisease
and
#BetaThalassemia
for the European Union. Learn more:
5
61
262
CRISPR Therapeutics and Vertex are pleased to share that we completed our regulatory submissions for exa-cel for sickle cell disease and beta thalassemia in the EU and the UK in December 2022.
7
41
250
We are pleased to announce that we’ve completed the submission of our Biologics License Applications (BLAs) to the U.S. FDA for our potential treatment for sickle cell disease and beta thalassemia. Learn more:
10
48
229
Today, we provided an update on our immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates and we announced expansion into autoimmune disease. Learn more here:
8
35
193
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the conditional approval of the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for
#SickleCellDisease
and
#BetaThalassemia
.
4
37
159
We are pleased to announce that FDA has accepted our biologics license applications for our potential treatment for sickle cell disease and transfusion-dependent beta thalassemia. Our application for sickle cell disease has been granted priority review:
4
28
131
CRISPR Therapeutics and Vertex are pleased to share that the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have validated the regulatory submissions of our potential treatment for sickle cell disease and beta thalassemia.
4
31
133
We’re at
#ASH21
alongside experts in the
#hematology
field to learn from our peers and spread awareness as we continue our work to potentially treat
#sicklecelldisease
,
#betathalassemia
and
#bloodcancers
. If you’re attending the
@ASH_hematology
meeting, come by our booth
#3323
.
1
16
109
In collaboration with Vertex Pharmaceuticals, we're pleased to share that we’ve published three new publications in The New England Journal of Medicine (NEJM) containing clinical data on the treatment for sickle cell disease and beta thalassemia.
5
21
102
Congratulations to Drs. Emmanuelle Charpentier and Jennifer Doudna on receiving the 2020
#NobelPrize
in Chemistry for their pioneering work on the CRISPR/Cas9 system!
0
27
101
We are pleased to announce that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™ for the treatment of relapsed or refractory CD19+ B-cell malignancies. Learn more here:
2
26
101
$CRSP and
@VertexPharma
announce early positive safety and efficacy data from the first two patients treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 for severe hemoglobinopathies. Learn more here:
0
50
99
We’re excited to announce that $CRSP received a
@gatesfoundation
grant to research in vivo gene editing therapies for HIV. Learn more here:
3
19
100
@CRISPRTX
will ring the Opening Bell at
@NasdaqExchange
in Times Square this morning to commemorate the first-ever approval of a CRISPR therapy and to celebrate innovation as our full pipeline advances. Tune in for the livestream here at 9:15am ET:
4
16
88
We are pleased to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™ for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS). Read more here:
2
14
81
The CRISPR era is here and we’re proud to be at the forefront. Thank you
@AtlanticLIVE
for inviting our CEO
@CrisprSam
to the
#AtlanticHealth
Summit to discuss how CRISPR is pioneering a new era of medicine with potential applications for a range of serious diseases.
#CRISPRTX
3
9
86
Today, $CRSP and
@VertexPharma
announced that the EMA has granted PRIME designation for our investigational CRISPR/Cas9 gene-editing program for transfusion-dependent
#BetaThalassemia
. Learn more here:
2
17
85
Today we announced that the FDA granted exa-cel a rolling review for the potential treatment of sickle cell disease and transfusion-dependent beta thalassemia. Read more here:
1
18
84
Our teams and investigators shared new clinical data on our investigational gene-edited therapy for the treatment of sickle cell disease and beta thalassemia at the
@EHA_Hematology
2023 Annual Congress. Learn more:
7
14
77
It was an exciting day as Dr. PK Morrow, our Chief Medical Officer, presented preclinical data on our investigational programs for the treatment of cardiovascular disease in two oral sessions at the
@American_Heart
Scientific Sessions. Learn more:
#AHA23
2
10
78
Today, we announced new preclinical data presented at the Annual Meeting of the American Society of Gene & Cell Therapy highlighting our approach to developing lipid nanoparticle (LNP) based delivery for in vivo ocular gene editing:
@ASGCTherapy
#ASGCT2024
2
21
77
We are pleased to announce that CTX001™ has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA for the treatment of severe hemoglobinopathies. Learn more here:
0
25
71
We are pleased to announce new clinical data on our investigational gene-edited therapy for the treatment of sickle cell disease and beta thalassemia at the
@EHA_Hematology
2022 Congress. Learn more:
#EHA2022
5
15
72
Today, $CRSP announced positive top-line results from Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies. Learn more here:
0
23
72
Thank you
@ARKInvest
for featuring
@CrisprSam
in a great discussion with
@CathieDWood
and
@aurmanARK
on the power of gene editing, innovation and more. Listen to the podcast here:
7
17
69
We are pleased to share that we have entered into a new non-exclusive licensing agreement with Vertex for the use of
@CRISPRTX
's gene editing technology to accelerate development of Vertex’s hypoimmune cell therapies for type-1 diabetes (T1D). Read more:
3
14
70
$CRSP and
@CapsidaBio
are excited to announce a strategic collaboration to develop in vivo gene editing therapies for
#ALS
and
#FriedreichsAtaxia
(FA). Read more:
3
11
69
On
#RareDiseaseDay
, our CEO Dr. Samarth Kulkarni
@CrisprSam
joined CNBC’s Power Lunch discussing the science of gene editing and opportunities to efficiently scale the use of
#CRISPR
technology for a range of serious diseases. Watch here:
2
15
70
We’re pleased to announce the acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy (
@ASGCTherapy
) 2024 Annual Meeting. Learn more here:
#ASGCT2024
1
15
67
Congratulations to our partners on today’s announcement that Vertex is acquiring ViaCyte. We look forward to collaborating with them on advancing our hypo-immune, multi-generation diabetes programs through the clinic.
4
8
59
We’re pleased to announce that Philippe Drouet has joined $CRSP as Chief Commercial Officer. Read more about his appointment here:
6
6
58
We celebrated the official opening of our
@CRISPRTX
R&D HQ in
#Boston
! We're excited for the impactful work we will accomplish in this space as we continue to focus on innovation that matters. Thank you
@bt_prop
&
@tishmanspeyer
for the collaboration on this facility.
0
13
58
This week,
@CRISPRTX
rang the Opening Bell at
@NasdaqExchange
in Times Square to celebrate our milestones and growth! We’re proud to ring in our success as a company and the impact we can have on people living with serious diseases:
📸: Nasdaq, Inc.
3
10
58
In collaboration with
@VertexPharma
, we announced new data at the
@ASH_hematology
Annual Meeting for our investigational gene-editing program for the treatment of sickle cell disease and beta thalassemia, and a
@NEJM
publication on this program.
#ASH20
0
13
56
We’re looking forward to presenting an oral presentation at the upcoming American Society of Gene & Cell Therapy (
@ASGCTherapy
) 2024 Annual Meeting on May 8, 2024. Learn more here:
#ASGCT2024
1
13
57
We’re pleased to present new preclinical data on our CAR-T program at the
#AACR21
annual meeting. Learn more here:
1
12
57
Thank you
@BlackRock
for having $CRSP CEO
@CrisprSam
on The Bid podcast to discuss how we have advanced clinical trials for CRISPR-based medicines to treat serious diseases including
#SickleCell
,
#BetaThalassemia
and cancer.
The
#Covid19
pandemic has changed the healthcare industry and made it more efficient.
@CrisprSam
, CEO of
@CRISPRTX
, joins The Bid podcast to discuss how. Listen:
8
5
24
2
11
55
Watch our newest video to learn more about
#CARTCells
and how they are designed to find and kill cancer cells: . Stay tuned for more information about CAR-T cells on our channel.
1
12
55
Today, we presented new positive data from our ongoing Phase 1 clinical trial of CTX130™ in relapsed or refractory T cell malignancies at the
@EHA_Hematology
2022 Congress. Learn more here:
#EHA2022
2
12
54
$CRSP will host a virtual event on October 12 at 4:30pm ET to highlight clinical data from its ongoing Phase 1 CARBON trial of CTX110™, its allogeneic CAR-T investigational therapy targeting CD19. Learn more here:
1
18
55
Today, $CRSP and
@VertexPharma
, announced that the companies have amended their collaboration agreement for our investigational CRISPR/Cas9 gene-editing program for severe hemoglobinopathies. Learn more here:
3
10
53
Our teams and investigators shared new clinical data and program updates at
#EHA2021
for our investigational gene-editing programs in sickle cell disease and beta thalassemia in partnership with
@VertexPharma
. Learn more:
4
14
51
We’re excited that an abstract on new data on our investigational gene-edited therapy for the treatment of sickle cell disease and beta thalassemia has been accepted as a late breaking presentation at the
@EHA_Hematology
2022 Congress. Learn more:
#EHA2022
0
7
48
During the Plenary Scientific Session at the
@ASH_hematology
Annual Meeting, $CRSP and
@VertexPharma
shared updated data on our gene-editing clinical program for severe sickle cell disease and transfusion-dependent beta thalassemia.
#ASH20
0
6
49
10 years ago today, the first scientific publication on
#CRISPRCas9
gene editing technology opened the door to a bold future of transformational medicine. We're proud to celebrate this milestone and to keep advancing science. Learn more about
#CRISPR
here:
2
19
49
$CRSP submits first clinical trial application in Europe for a CRISPR-based therapy in beta-thalassemia
2
34
48
Congratulations to our co-founder Emmanuelle Charpentier and
@UCBerkeley
professor Jennifer Doudna on winning the 2020 Wolf Prize in Medicine for their pioneering work in CRISPR-Cas9 gene-editing technology! Learn more here:
2
6
48
#Breaking
: Today, $CRSP and
@VertexPharma
announced new clinical data and progress for CTX001™ in severe hemoglobinopathies at the
#EHA25Virtual
Congress. Learn more here:
1
14
47
Ready to be at the forefront of
#geneediting
? We’re hiring a Gene Editing Innovator in Boston to drive research initiatives and help us continue building cutting-edge
#CRISPR
technologies. Learn more about this opportunity here: .
2
15
43
Today, we announced our third quarter earnings results. Read more about our recent highlights and outlook:
1
11
47
Today, $CRSP announced our 1Q 2021 financial results. Want to learn more about our recent highlights? Check out our business update released today:
2
7
45
We’re pleased to announce that Alex Harding, M.D., M.B.A., is joining us as Senior Vice President and Head of Business Development. Read more about his appointment here:
2
3
48
Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook:
2
3
46
In a new video interview, our CEO Dr. Samarth Kulkarni discusses how advancements in cell and gene therapy innovation can shape the future of medicine for patients across the globe. Learn more here:
2
10
44
Today $CRSP announced that we are building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of our investigational cell therapy product candidates. Learn more here:
0
17
45
Ever wondered how chimeric antigen receptors, or
#CARTCells
, are designed to kill cancer cells? Check out the animation below to learn more about CAR T technology.
0
11
44
We’re excited to expand our collaboration with
@VertexPharma
to develop best-in-class gene-edited therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1. Learn more here: $CRSP
1
16
45
Today, we announced our second quarter earnings results. Read more about our recent highlights and outlook:
3
2
43
We’re proud to be recognized as the
#1
employer in
@biospace
's 2022
#BestPlacestoWork
report, among top biopharma employers with <1,000 employees. This survey spotlights companies that life sciences professionals consider top choice employers. Read more:
0
5
44
At CRISPR, we believe in equal access to quality health care. National Minority Health Month highlights the strides taken to decrease medical disparities affecting underrepresented communities while acknowledging there is more work to be done.
2
8
43
"We’re now talking about an intelligent drug." -
@CRISPRSam
Watch the full interview:
#unitetoprevent
@curafdn
@vaticancultura
4
16
39
Watch this video to learn how CRISPR/Cas9 gene editing technology is being investigated for the treatment of
#hemoglobinopathies
such as sickle cell disease and beta thalassemia.
1
12
40
We celebrate the women who are laying the foundation for our success at
@CRISPRTX
on
#February11
, International Day of Women and Girls in Science. We honor them – as well as all the pioneering women who are inspiring tomorrow's
#STEM
leaders.
#WomenInScience
#CRISPR
#CRISPRTX
2
8
41
We’re excited to welcome Naimish Patel, M.D., who is joining
@CRISPRTX
as Chief Medical Officer. Dr. Patel brings extensive drug development experience and proven leadership, which will be critical as we continue to advance our pipeline. Learn more here:
1
6
41
Thank you
@Forbes
for featuring
@CrisprSam
in a great discussion with
@DrMichelleBIO
on the power of gene editing
#ForbesHealth
.
@CRISPRTX
CEO
@CrisprSam
Kulkarni on gene editing and whether that can cure sickle cell disease
#ForbesHealth
2
10
33
1
9
40
As
#precisionhealth
and individualized medicine play a greater role in health care,
@DCRINews
,
@CRISPRTX
,
@Beamtx
,
@Intelliatx
, &
@Vervetx
are partnering on the new
#PrecisionHealthAlliance
, focused on innovation in gene editing. Learn more here:
1
9
41
Today, we announced our second quarter earnings results. Read more about our recent highlights and outlook:
4
5
39
Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook:
2
7
39
$CRSP and
@VertexPharma
announce that the U.S. FDA granted Fast Track Designation for CRISPR gene-edited therapy CTX001 for the treatment of
#betathalassemia
. Learn more here:
0
12
39
Today, $CRSP and
@VertexPharma
announced that the EMA has granted PRIME designation to CTX001, for the treatment of severe
#SickleCellDisease
. Learn more here:
0
7
36
On April 4th at 10am ET, our CEO Dr. Samarth Kulkarni
@CrisprSam
will join
@TheAtlantic
's Health Summit to discuss the future of gene-editing technology. Learn more and register here:
#AtlanticHealth
0
8
38
#SickleCellDisease
(SCD) affects red blood cells in the body and is one of the most commonly inherited conditions worldwide.
#WorldSickleCellDay
aims to strengthen global
#SCD
communities, spread awareness, and
#BreakTheChain
.
1
2
37
Today, $CRSP, in collaboration with
@VertexPharma
, announced the plenary presentation of new data for CTX001™ at the upcoming
#ASH20
meeting. Learn more here:
0
10
36
Thank you
@IAmBiotech
for hosting a panel at
#BIOCEO23
on CRISPR’s role in next-generation gene-based therapies.
@CRISPRTX
’s Julie Bruno, Head of Portfolio & Program, discussed the importance of
#innovation
in advanced gene editing to help patients in need.
#CRISPRTX
2
3
37
Today, we announced our first quarter earnings results. Read more about our recent highlights and outlook:
0
4
34
CRISPR-X is a dedicated internal group within CRISPR Therapeutics focused on emerging technologies well-suited to advancing development and delivery of gene-editing therapies to patients. Explore careers with our growing team in San Francisco and Boston: .
2
12
35
We're excited to share that our CEO Dr. Samarth Kulkarni will be speaking on a panel at
#AspenIdeasHealth
tomorrow (Friday, June 21) at 11:40am MT / 1:40pm ET about ways to expand on the broad potential for the
#CRISPR
technology. Tune in here:
@aspenideas
1
6
36
We're pleased to invite Christian Rommel, Ph.D., to join our Board of Directors. His extensive experience accelerating innovation and advancing drug candidates across modalities will be invaluable as we continue to advance our platform and pipeline:
2
5
37
SAVE THE DATE: We will host an Innovation Day focused on early research and development on June 21 at 2:00 PM ET. Please find information here: $CRSP
1
8
34
$CRSP provides business update and reports 4Q 2020 financial results. Learn more in our press release:
5
4
37